Alzheimer's disease (AD) is the most common form of neurodegenerative dementia that is
rapidly becoming a major health problem, especially in developed countries because of …

Alzheimer's disease (AD) is the predominant neurodegenerative disorder, affecting
approximately 60–80% of all patients diagnosed with dementia globally. Given the intricate …

A person suspected of having Alzheimer's disease (AD) is clinically diagnosed for the
presence of principal biomarkers, especially misfolded amyloid-beta (Aβ) and tau proteins in …

The diagnosis of Alzheimer's disease (AD) took a major step forward in 2012, as Food and
Drug Administration approved the first positron emission tomography tracer. In parallel to …

Optimized theranostic strategies for Alzheimer's disease (AD) remain almost absent from
bench to clinic. Current probes and drugs attempting to prevent β‐amyloid (Aβ) fibrosis …

Early detection of Alzheimer's disease (AD) is imperative in enabling the understanding and
clinical treatment of this disorder, as well as in preventing its progression. Imaging agents …

Alzheimer's Disease (AD) remains one of the most challenging health-related issues for our
society. It is becoming increasingly prevalent, especially in developed countries, due to the …

Diagnosis of Alzheimer's disease (AD) is crucial especially for the complete comprehension
of pathology and clinical therapy of the disorder, as well as in declining the severity of the …

Near-infrared (NIR) fluorescent imaging of both soluble and insoluble Aβ species in the
brain of Alzheimer's disease (AD) is crucial for the early diagnosis and intervention of AD. To …

Alzheimer's disease (AD) is the most common form of dementia. The pathogenesis of the
disease is associated with aggregated amyloid-β, hyperphosphorylated tau, a high level of …